Thomson Reuters' Pharma Matters highlights Vaccinogen’s OncoVAX® as “One to Watch”

Quarterly Reports Utilize Strategic Intelligence and Competitive Analysis from Thomson Reuters to Analyze Promising Drugs Changing Clinical Phase, Leading Sources of Information on Medical Research and the U.S. Generics Market

Jun 4, 2008

LONDON and PHILADELPHIA, June 4, 2008/PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of the Pharma Matters reports covering the time period October-December 2007. The Pharma Matters quarterly report series was launched two years ago and covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).
Who is Making the Biggest Splash?
This report is a Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the listed 15 organizations that have made the biggest impact as the leading sources of information on medical research from October-December 2007 are:

1. Bristol-Myers Squibb
2. Eli Lilly
3. Pfizer
4. GlaxoSmithKline
5. AstraZeneca

To see the complete list, as well as analysis and methodology, click to read the full report:
The Ones to Watch
A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on the strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q4 2007, the top five of the most promising drugs launched or receiving approval were:

ATryn(R) Hereditary antithrombin deficiency GTC Biotherapeutics/ LEO Pharma
OncoVAX(R) Colon cancer, melanoma, renal cell carcinoma Vaccinogen
Ixempra(TM) Breast cancer Bristol-Myers Squibb
Isentress(TM) HIV-1 Infection Merck & Co
Perforomist(TM) Inhalation Solution Chronic obstructive pulmonary disease Dey

More analysis, as well as information on drugs entering clinical Phases I, II and III, are available in the full report: (Due to length of URL, Please copy and paste link into browser. Remove the space if one exists.)
Movers and Shakers
Introduced in mid-2007, this report is the newest in the Pharma Matters series and covers the U.S. generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q4 2007 report includes:

  •  2007 was a year of unprecedented competition in the US generics market, driven primarily by the number of new players entering the Generics field.
  • ANDA approvals climbed to a record of more than 480, an increase from 365 the previous year. Paragraph IV patent challenges also continued at a fierce pace.
  • Forty different drug products were exposed to paragraph IV challenges for the first time in 2007, almost a doubling of the 24 in 2006.
  • During the last quarter of 2007, the largest number of ANDA approvals went to US-based companies.
  • In the same time period, nine India-based companies received a total of 21 approvals, putting India in second place.
  • In the previous quarter, Indian-based companies were the leaders in terms of ANDA approvals with 51, while US-based companies received a total of 44 approvals.

To learn more about companies making their mark on the U.S. generics market, click on this link to read the full report: -dec07.pdf (Due to length of URL, Please copy and paste link into browser. Remove the space if one exists.)
To sign up for the Thomson Reuters Pharma Matters series of publications visit:
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to
SOURCE The Scientific business of Thomson Reuters


print email rss